Cargando…
CYP2C19 metabolizer phenotypes may affect the efficacy of statins on lowering small dense low-density lipoprotein cholesterol of patients with coronary artery disease
BACKGROUND: Dyslipidemia is a major cause of arteriosclerotic cardiovascular disease (ASCVD), and low-density lipoprotein cholesterol (LDL-C) is the profile to be reduced to prevent disease progression. Small dense low-density lipoprotein cholesterol (sdLDL-C) has been proven to be a more effective...
Autores principales: | Dai, Ruozhu, Zhao, Xiaoyu, Zhuo, Huilin, Wang, Wei, Xu, Yue, Hu, Zixin, Zhang, Tiexu, Zhao, Jiangman |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806256/ https://www.ncbi.nlm.nih.gov/pubmed/36601065 http://dx.doi.org/10.3389/fcvm.2022.1016126 |
Ejemplares similares
-
Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol
por: Bardolia, Chandni, et al.
Publicado: (2021) -
Small, Dense Low-Density Lipoprotein-Cholesterol and Atherosclerosis: Relationship and Therapeutic Strategies
por: Jin, Xiao, et al.
Publicado: (2022) -
Low-density lipoprotein-cholesterol lowering effect of a nutraceutical regimen with or without ezetimibe in hypercholesterolaemic patients with statin intolerance
por: Ward, Natalie C., et al.
Publicado: (2022) -
Low-Density Lipoprotein Cholesterol 4: The Notable Risk Factor of Coronary Artery Disease Development
por: Wu, Dongmei, et al.
Publicado: (2021) -
Achievement of low-density lipoprotein cholesterol targets in Chinese patients with atherosclerotic cardiovascular disease after receiving statins and ezetimibe
por: Cheng, Yinchu, et al.
Publicado: (2022)